Clinical use of tumor markers based on outcome analysis

Laboratory Medicine

Volumn 27, Issue 12, 1996, Pages 817-821

  Aziz, Douglas C ^a  

^a Specialty Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; TUMOR MARKER;

CHORIOCARCINOMA; DIAGNOSTIC VALUE; HUMAN; HYDATIDIFORM MOLE; LIVER CANCER; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OVARY CANCER; PANCREAS CANCER; PATIENT MONITORING; PREDICTION; REVIEW; SCREENING TEST; TREATMENT OUTCOME; TROPHOBLASTIC DISEASE; TUMOR RECURRENCE;

EID: 0029906687     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1093/labmed/27.12.817     Document Type: Review

References (45)

1. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
2. Mogensen O, Mogensen B, Jakobsen A. CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol. 1989;25:1187-1190.
3. Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P. Comparison of tumor-associated trypsin inhibitor (TATI) with CA 125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest. 1991;51(suppl 207):19-24.
4. Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44:147-154.
5. Zurawski VR, Sjovall K, Schoenfeld DA, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 1990;36:299-305.
6. Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol. 1987;69:606.
7. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology - a review. Eur J Obstet Gynecol Reprod Biol. 1993;49:115-124.
8. Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA 125 level? Gynecol Oncol. 1994;53:93-97.
9. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 1994;121:124-132.
10. Bourne TH, Campbell S, Reynolds K, et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol. 1994;52:379-385.
11. Antoni J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res. 1995;15:1527-1532.
12. Sliutz G, Tempfer C, Kainz CH, et al. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Res. 1995;15:1127-1130.
13. Gallion HH, Hunter JE, van Nagell JR, et al. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. Gynecol Oncol. 1992;46:29-32.
14. Tomas C, Kauppila A. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma. Br J Cancer. 1993;45:279-283.
15. Stenman U-H, Alfthan H, Vartiainen J, Lehtovirta P. Markers supplementing CA 125 in ovarian cancer. Ann Med. 1995;27:115-120.
16. Healy DL, Burger GH, Mamers P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med. 1993;329:1539-1542.
17. Lappöhn RE, Burger GH, Bouma J, Bangah M, Krans M, de Bruijn WA. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321:790-793.
18. Kuusela P, Haglunk C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991;63:636-640.
19. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992;65:215-221.
20. Moertal CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943-947.
21. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-519.
22. Geer RJ, Brenna MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-73.
23. Diez M, Cerdáni FJ, Pollán M, et al. Prognostic significance of preoperative serum CA 19-9 assay in patients with colorectal carcinoma. Anticancer Res. 1994;14:2819-2826.
24. Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Jpn J Surg. 1995;24:518-525.
25. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489-5492.
26. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992;215:350-355.
27. Sperti C, Pasquali C, Catalini S, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52:137-141.
28. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas. 1994;9:731-734.
29. Regelson W. Have we found the "definitive cancer biomarker"? Cancer. 1995;76:1299-1301.
30. Bartlett NL, Freiha FS, Torti FM. Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am. 1991;5:1245-1260.
31. Fowler JE Jr, Taylor G, Blom J, Stutzman RE. Experience with serum alpha-fetoprotein and human chorionic gonadotropin in non-seminomatous testicular tumors. J Urol. 1980;124:365-368.
32. Bagshawe KD. Choriocarcinoma. A model for tumour markers. Rev Oncol. 1992;5:99-106.
33. DuBeshter B, Berkowitz RS, Goldstein DP, Bernstein MR. Analysis of treatment failure in high-risk metastatic gestational trophoblastic disease. Gynecol Oncol. 1988;29:199-207.
34. Saller B, Clara R, Spottl G, Siddle K, Mann K. Testicular cancer secretes intact human choriogonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up. Clin Chem. 1990;36:234-239.
35. Anderson T, Waldman TA, Javadpour N, et al. Testicular germ-cell neoplasms: recent advances in diagnosis and therapy. Ann Intern Med. 1979;90:373-385.
36. Bosl GJ, Lange PH, Fraley EE, et al. Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. Cancer. 1981;47:328-332.
37. Williams MP, Husband JE, Heron CW. Stage I nonseminomatous germ cell tumors of the testis: radiologic follow-up after orchidectomy. Radiology. 1987;164:671-674.
38. Thompson PI, Nixon J, Harvey JV. Disease relapse in patients with stage I non-seminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol. 1988;6:1597-1603.
39. Rüther U, Rothe B, Grunert K, et al. Role of human chorionic gonadotropin in patients with pure seminoma. Eur Urol. 1994;26:129-133.
40. Deutsch HF. Chemistry and biology of α-fetoprotein. Adv Cancer Res. 1991;56:253-312.
41. Klepp O. Serum tumour markers in testicular and extragonadal germ cell malignancies. Ann Oncol. 1990;1:281-288.
42. Heyward WL, Lanier AP, McMahon BJ, Fitzgerald MA, Kilkenny S, Paprochi TR. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA. 1985;254:3052-3054.
43. Lee H-S, Chung YH, Kim CY. Specificities of serum α-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology. 1991;14:68-72.
44. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802-1806.
45. Skiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995;22:802-807.